arrow
D

Daniel G. Stover

the ohio state university comprehensive cancer center james cancer hospital and solove research institute
H指数:43
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer

Oncotype DX风险分层和化疗接受情况对微小淋巴结阴性HR+乳腺癌患者生存结局的影响

2026-07-150
OAAI
Disulfiram metabolite Cu(DDC)2 enhances radionuclide uptake in vivo revealing insights into tumoural ablation resistance

二硫化二乙基氨基甲酸铜(Cu(DDC)2)这种二硫化物代谢物能增强体内放射性核素摄取,揭示了关于肿瘤消融抵抗的见解。

2026-02-110
OAAI
Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer

三模态疗法与单纯化疗相比,在转移性炎性乳腺癌患者中与更高的总生存期相关。

2025-12-160
PRE
Using Group Concept Mapping to Define Priorities for Lymphedema Care and Research

运用群体概念映射法确定淋巴水肿护理与研究的优先事项

2025-11-010
PRE
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report

Sacituzumab govitecan和立体定向放射手术治疗HER2阴性乳腺癌脑转移瘤:一项多中心报告

2025-09-300
PRE
Isolated oral CD30+/CD4+ CAR+ T-cell lymphoma in long-term remission after radiotherapy

孤立性口腔CD30+/CD4+ CAR+ T细胞淋巴瘤在放疗后的长期缓解

2025-09-020
OAAI
Invasive lobular carcinoma: integrated multi-omics analysis reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance

浸润性小叶癌:整合多组学分析揭示他莫昔芬耐药中精氨酸琥珀酸合酶的沉默及核苷酸生物合成的上调

2025-07-110
OAAI
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

T细胞免疫检查点抑制联合低甲基化治疗局部晚期HER2-negative乳腺癌: 地西他滨和派姆单抗联合标准新辅助化疗的2期新辅助窗口试验

2025-02-270
OA
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

MEK抑制剂曲美替尼单独或与AKT抑制剂GSK2141795/乌普罗替尼联合治疗转移性三阴性乳腺癌患者的II期研究

2024-12-071
PRE
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
2024-11-010
OAAI
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status

早期三阴性乳腺癌新辅助化疗后HER2-low状态的临床疗效分析

2024-11-010
OAAI